机构：[1]Department of Gastrointestinal Surgery, Institute of Digestive Surgery and State key Laboratory of Biotherapy,West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China四川大学华西医院[2]Department of Oncology, andDepartment of Clinical and Experimental Medicine, Linköping University, Linköping, SE 58183, Sweden[3]Department of Paediatric Surgery, Institute of Digestive Surgery and State key Laboratory of Biotherapy, WestChina Hospital, Sichuan University, Chengdu, Sichuan 610041, China[4]Department of Surgery, and Departmentof Clinical and Experimental Medicine, Linköping University, Norrköping, SE 60174, Sweden[5]Department ofpathology, Lund University, Lund, SE 22100, Sweden[6]School of Medicine, Örebro University, Örebro, SE 70182,Sweden
The incidence of colorectal cancer (CRC) in young patients (≤ 50 years of age) appears to be increasing. However, their clinicopathological characteristics and survival are controversial. Likewise, the biomarkers are unclear. We used the West China (2008-2013, China), Surveillance, Epidemiology, and End Results program (1973-2011, United States) and Linköping Cancer (1972-2009, Sweden) databases to analyse clinicopathological characteristics, survival and multiple biomarkers of young CRC patients. A total of 509,934 CRC patients were included from the three databases. The young CRC patients tended to have more distal location tumours, fewer tumour numbers, later stage, more mucinous carcinoma and poorer differentiation. The cancer-specific survival (CSS) of young patients was significantly better. The PRL (HR = 12.341, 95% CI = 1.615-94.276, P = 0.010), RBM3 (HR = 0.093, 95% CI = 0.012-0.712, P = 0.018), Wrap53 (HR = 1.952, 95% CI = 0.452-6.342, P = 0.031), p53 (HR = 5.549, 95% CI = 1.176-26.178, P = 0.045) and DNA status (HR = 17.602, 95% CI = 2.551-121.448, P = 0.001) were associated with CSS of the young patients. In conclusion, this study suggests that young CRC patients present advanced tumours and more malignant pathological features, while they have a better prognosis. The PRL, RBM3, Wrap53, p53 and DNA status are potential prognostic biomarkers for the young CRC patients.
基金：
Swedish Cancer Foundation, Swedish Research Council
and the Health Research Council in the South-East of Sweden, and the National Scientific Foundation
of China (Grant NO. 81401949, 8130035).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2015]版：
大类|2 区综合性期刊
小类|2 区综合性期刊
最新[2023]版：
大类|2 区综合性期刊
小类|2 区综合性期刊
第一作者：
第一作者机构：[1]Department of Gastrointestinal Surgery, Institute of Digestive Surgery and State key Laboratory of Biotherapy,West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China[2]Department of Oncology, andDepartment of Clinical and Experimental Medicine, Linköping University, Linköping, SE 58183, Sweden
共同第一作者：
通讯作者：
通讯机构：[1]Department of Gastrointestinal Surgery, Institute of Digestive Surgery and State key Laboratory of Biotherapy,West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China[2]Department of Oncology, andDepartment of Clinical and Experimental Medicine, Linköping University, Linköping, SE 58183, Sweden
推荐引用方式(GB/T 7714)：
Wang Mo-Jin,Ping Jie,Li Yuan,et al.The prognostic factors and multiple biomarkers in young patients with colorectal cancer.[J].Scientific reports.2015,5:10645.doi:10.1038/srep10645.
APA：
Wang Mo-Jin,Ping Jie,Li Yuan,Adell Gunnar,Arbman Gunnar...&Sun Xiao-Feng.(2015).The prognostic factors and multiple biomarkers in young patients with colorectal cancer..Scientific reports,5,
MLA：
Wang Mo-Jin,et al."The prognostic factors and multiple biomarkers in young patients with colorectal cancer.".Scientific reports 5.(2015):10645
